In Other News · United States · Markets

‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

Source: MarketWatch

Summary

The Federal Trade Commission and seven states say Shkreli should be held in contempt

You'll be taken to www.marketwatch.com

Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.